促红细胞生成素与血液兴奋剂。
Erythropoietin and blood doping.
作者信息
Robinson N, Giraud S, Saudan C, Baume N, Avois L, Mangin P, Saugy M
机构信息
Swiss Laboratory for Doping Analyses, Institute of Legal Medicine, Lausanne, Switzerland.
出版信息
Br J Sports Med. 2006 Jul;40 Suppl 1(Suppl 1):i30-4. doi: 10.1136/bjsm.2006.027532.
OBJECTIVE AND METHOD
To outline the direct and indirect approaches in the fight against blood doping in sports, the different strategies that have been used and are currently being used to fight efficiently against blood doping are presented and discussed.
RESULTS AND CONCLUSIONS
The paper outlines the different approaches and diagnostic tools that some federations have to identify and target sports people demonstrating abnormal blood profiles. Originally blood tests were introduced for medical reasons and for limiting misuse of recombinant human erythropoietin (rHuEPO). In this way it became possible to prevent athletes with haematocrit levels well above normal, and potentially dangerous for their health, competing in sport. Today, with nearly a decade of blood testing experience, sports authorities should be familiar with some of the limitations and specially the ability of blood tests performed prior to competitions to fight efficiently against the misuse of rHuEPO, blood transfusion, and artificial haemoglobin.
目的与方法
为概述体育界反血液兴奋剂斗争中的直接和间接方法，介绍并讨论了过去和目前为有效打击血液兴奋剂而采用的不同策略。
结果与结论
本文概述了一些联合会用以识别和针对血液指标异常运动员的不同方法和诊断工具。最初引入血液检测是出于医学原因以及限制重组人促红细胞生成素（rHuEPO）的滥用。通过这种方式，能够防止血细胞比容水平远高于正常且可能对健康有潜在危险的运动员参加体育比赛。如今，凭借近十年的血液检测经验，体育管理机构应熟悉一些局限性，特别是赛前进行的血液检测在有效打击rHuEPO滥用、输血和人工血红蛋白方面的能力。
Zotero 插件